Investee Company：Immune—onc Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors...

Oceanpine Capital today announced that it has appointed Wei Zhu to the position of Venture Partner...

MingMed Biotechnology, a startup that develops pharmaceutical products, has completed raising nearly $50 million in its Series A+ round...

FerroTec, a maker of semiconductor wafers, has raised 3.3 billion yuan ($511 million) in a Series B round of financing to advance its manufacturing capability, according to a statement...

Caocao Chuxing, the ride-hailing arm of automaker Geely, announced the completion of Round B financing worth 3.8 billion yuan ($589 million) on Monday...

Beijing (Gasgoo)- Wuhan AutoChips, a wholly controlled subsidiary of Hefei AutoChips, has completed its angel financing round with RMB100 million raised and Chinese smart phone maker OPPO...

​​​​​​​August 23, 2021, Mr. Dave Chenn, CEO of Oceanpine Capital led the company's investment team visited the National Engineering Laboratory for Electric Vehicles...

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the U.S. Food and Drug Administration (FDA) has cleared the

BEIJING, Aug. 9, 2021, Oceanpine Capital investee company—YishengBio Co., Ltd ("YishengBio") today announced that it received IND clearance for PIKA recombinant COVID-19 vaccine (CHO cell...

On August 14，the signing ceremony of Oceanpine Capital investee company— LionGo New Energy and Bieqiao Town, Liyang City was successfully held...